NCT07472972Recrutement en cours
Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)
Résumé
The INTeRCePT 2 study aims to develop a predictive assay to determine which patients with B cell lymphoma are most likely to respond to CAR T cell therapy. This assay combines five components for longitudinal profiling of each patient. The goal of the trial is that the assay can be completed (feasibility). This comprehensive assay integrates five key components including circulating tumor DNA (CAPPseq), inflammation markers from peripheral blood tests (InflaMIX), PET CT imaging parameters, immune cell profiles (flow cytometry), and performance status (ECOG). Ultimately, this tool could improve treatment selection, and guide more personalized therapy decisions for lymphoma patients receiving CAR T cells.
Critères d'inclusion
• Written informed consent before registration and prior to any trial specific procedures • Participants ≥ 18 years of age • Diagnosis of relapse/refractory B-cell lymphoma according to WHO 2022 classification • Measurable disease per response criteria specific to the disease e.g. per Lugano 2014 criteria • Patients planned for CD19-redirected CAR T cell therapy according to clinical standard of care • Patients who are willing to donate peripheral blood and biopsy material at indicated clinical visits
Critères d'exclusion
• Any condition, which precludes initiation of CD19-redirected CAR T cell therapy (e.g. breast feeding, pregnancy, infections, etc.) as judged by the treating physician • Any coexisting medical or psychological condition that would preclude participation in the required study procedures, as judged by the treating physician • Unwillingness or inability to comply with the protocol
Contacts
Les coordonnées de l'équipe de l'essai s'affichent sur demande.
Voir la fiche officielle de l'essai- Statut
- Recrutement en cours
- Phase
- —
- Type d'étude
- Observationnelle
- Pays
- Suisse
- Promoteur
- University of Zurich(Autre)
- N° de protocole
- INTeRCePT2.0
- Pathologies
- Lymphoma, Lymphoid Hematological Malignancies
- Interventions
- —
Collaborateurs
University Hospital, Zürich, ETH Zurich
Lieux · 1
- Zurich, SuisseUniversityhospital Zurich, Department of Medical Oncology and HematologyRecrute dans ce centre
Au total, dans le monde, le seul centre listé au registre recrute.
Statut par centre selon le registre ClinicalTrials.gov (dernière mise à jour publiée : 16 mars 2026).
Ce statut peut avoir changé et ne dit rien de votre éligibilité : avant toute démarche, vérifiez avec votre oncologue ou le centre.
Autres identifiants
- BASEC-Nr. 2024-02540 · autre identifiant
Voir aussi
Autres versions
Ces résultats sont indicatifs et ne remplacent pas un avis médical — à discuter avec votre médecin.